Replimune cries foul on regulatory flexibility. But many Americans want a stricter FDA
BioSpace
After Replimune's advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency's lack
pharminent
April 17, 2026 (Last updated: April 17, 2026)
BioSpace
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack
